
Benjamin Jean Gaborit

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5304151/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiology and Clinical Impact of Respiratory Coinfections at Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia. Journal of Infectious Diseases, 2022, 225, 868-880.	4.0	5
2	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infectious Diseases, The, 2022, 22, 209-221.	9.1	233
3	Potential Impact of Rapid Multiplex PCR on Antimicrobial Therapy Guidance for Ventilated Hospital-Acquired Pneumonia in Critically III Patients, A Prospective Observational Clinical and Economic Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804611.	3.9	12
4	Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study. Clinical Microbiology and Infection, 2021, 27, 1015-1021.	6.0	15
5	Resurgence of BK virus following Covidâ€19 in kidney transplant recipients. Transplant Infectious Disease, 2021, 23, e13465.	1.7	5
6	Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic). Arthritis Research and Therapy, 2021, 23, 70.	3.5	12
7	Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial. Trials, 2021, 22, 199.	1.6	14
8	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 522-532.	10.7	195
9	Circulating Regulatory T Cells Expressing Tumor Necrosis Factor Receptor Type 2 Contribute to Sepsis-Induced Immunosuppression in Patients During Septic Shock. Journal of Infectious Diseases, 2021, 224, 2160-2169.	4.0	8
10	Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. Immunity, 2021, 54, 1578-1593.e5.	14.3	75
11	Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study. Antimicrobial Agents and Chemotherapy, 2021, 65, e0123721.	3.2	13
12	Contribution of lung ultrasound in diagnosis of community-acquired pneumonia in the emergency department: a prospective multicentre study. BMJ Open, 2021, 11, e046849.	1.9	5
13	Treatment of UTIs Due to Klebsiella pneumoniae Carbapenemase-Producers: How to Use New Antibiotic Drugs? A Narrative Review. Antibiotics, 2021, 10, 1332.	3.7	8
14	XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. Frontiers in Immunology, 2021, 12, 761250.	4.8	7
15	Reaching the Second and Third Joint United Nations Programme on Human Immunodeficiency Virus (HIV)/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary HIV Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort. Clinical Infectious Diseases, 2020, 71, 293-300.	5.8	14
16	Long-term Outcome of Patients With Nonoperated Prosthetic Valve Infective Endocarditis: Is Relapse the Main Issue?. Clinical Infectious Diseases, 2020, 71, 1316-1319.	5.8	16
17	Switch from parenteral to oral antibiotics for brain abscesses: a retrospective cohort study of 109 patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 3062-3066.	3.0	9
18	Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations. International Journal of Legal Medicine, 2020, 134, 2209-2214.	2.2	51

#	Article	IF	CITATIONS
19	Treatment of Bone and Joint Tuberculosis in France: A Multicentre Retrospective Study. Journal of Clinical Medicine, 2020, 9, 2529.	2.4	9
20	Regulatory T Cells Expressing Tumor Necrosis Factor Receptor Type 2 Play a Major Role in CD4+ T-Cell Impairment During Sepsis. Journal of Infectious Diseases, 2020, 222, 1222-1234.	4.0	13
21	Evaluation of the FilmArray® Pneumonia Plus Panel for Rapid Diagnosis of Hospital-Acquired Pneumonia in Intensive Care Unit Patients. Frontiers in Microbiology, 2020, 11, 2080.	3.5	21
22	Pseudomonas aeruginosa Infection Impairs NKG2D-Dependent NK Cell Cytotoxicity through Regulatory T-Cell Activation. Infection and Immunity, 2020, 88, .	2.2	3
23	Nocardiosis in graft recipients of kidneys from extendedâ€criteria donors following switch to belatacept complicated by acute rejection. Transplant International, 2020, 33, 1565-1568.	1.6	1
24	Respiratory Mechanics and Outcomes in Immunocompromised Patients With ARDS. Chest, 2020, 158, 1947-1957.	0.8	12
25	A murine model of Staphylococcus aureus infected chronic diabetic wound: A new tool to develop alternative therapeutics. Wound Repair and Regeneration, 2020, 28, 400-408.	3.0	3
26	Development and validation of a dosing nomogram for amoxicillin in infective endocarditis. Journal of Antimicrobial Chemotherapy, 2020, 75, 2941-2950.	3.0	7
27	Plea for multitargeted interventions for severe COVID-19. Lancet Infectious Diseases, The, 2020, 20, 1122-1123.	9.1	18
28	Ludwig's angina: A diagnostic and surgical priority. International Journal of Infectious Diseases, 2020, 93, 160-162.	3.3	18
29	Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. Lancet Infectious Diseases, The, 2020, 20, 1014-1015.	9.1	180
30	Should we reconsider cefazolin for treating staphylococcal meningitis? A retrospective analysis of cefazolin and cloxacillin cerebrospinal fluid levels in patients treated for staphylococcal meningitis. Clinical Microbiology and Infection, 2020, 26, 1415.e1-1415.e4.	6.0	19
31	Lopinavir pharmacokinetics in COVID-19 patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 2702-2704.	3.0	52
32	Population Pharmacokinetic Study of Cefazolin Dosage Adaptation in Bacteremia and Infective Endocarditis Based on a Nomogram. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	13
33	Influenza and associated co-infections in critically ill immunosuppressed patients. Critical Care, 2019, 23, 152.	5.8	21
34	Listeria Endophthalmitis cured with Linezolid in an Immunocompetent Farmer Woman: Hazard of a Sweep of a Cow Tail. Open Forum Infectious Diseases, 2019, 6, ofz459.	0.9	1
35	High-Dosage Cefazolin Achieves Sufficient Cerebrospinal Diffusion To Treat an External Ventricular Drainage-Related <i>Staphylococcus aureus</i> Ventriculitis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
36	Risk-benefit Assessment of Systematic Thoracoabdominal-pelvic Computed Tomography in Infective Endocarditis. Clinical Infectious Diseases, 2019, 69, 1605-1612.	5.8	11

Benjamin Jean Gaborit

#	Article	IF	CITATIONS
37	Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study. Annals of Intensive Care, 2019, 9, 131.	4.6	47
38	Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	4
39	1086. Impact of Systematic Thoraco-Abdomino-Pelvic CT Scan on the Diagnosis of Infective Endocarditis. Open Forum Infectious Diseases, 2018, 5, S325-S325.	0.9	0
40	Résistances bactériennesÂ: que doit savoir l'urologueÂ?. Progrès En Urologie - FMC, 2018, 28, F103-F10	060.1	0
41	Characteristics and outcome of multidrug-resistant tuberculosis in a low-incidence area. Médecine Et Maladies Infectieuses, 2018, 48, 457-464.	5.0	11
42	Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments. Journal of Antimicrobial Chemotherapy, 2017, 72, 2135-2136.	3.0	15
43	Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Medicine, 2017, 43, 1808-1819.	8.2	176
44	Salvage B-cell depletion therapy in rapidly progressive dermatomyositis-associated interstitial lung disease. Joint Bone Spine, 2014, 81, 192-193.	1.6	3